Lys-bradykinin | 342-10-9

• 分子结构分类: 有机化合物 - 有机聚合物 - 多肽
• 英文名称: Lys-bradykinin
• 英文别名: kallidin；KRPPGFSPFR；lysyl-bradykinin；(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[[(2S)-1-[(2S)-1-[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid
• CAS: 342-10-9
• 化学式: C₅₆H₈₅N₁₇O₁₂
• 分子量: 1188.4
• InChiKey: FYSKZKQBTVLYEQ-FSLKYBNLSA-N

物化性质

• 比旋光度：
  D21 -57° (c = 1 in N acetic acid)

计算性质

• 辛醇/水分配系数(LogP)：
  -5.3
• 重原子数：
  85
• 可旋转键数：
  33
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  474
• 氢给体数：
  14
• 氢受体数：
  16

反应信息

• 作为产物：
  描述：

  ortho-aminobenzoic acid-MISLMKRPPGFSPFRSSRI-NH2 生成 舒缓激肽 、 蛋氨酸-赖氨酸-缓激肽 、 Lys-bradykinin
  参考文献：
  名称：

  摘要：

  DOI：

文献信息

• Pharmaceutical compositions of drug-oligomer conjugates and methods of treating diseases therewith
  申请人：——

  公开号：US20030069170A1

  公开（公告）日：2003-04-10

  Pharmaceutical compositions that include a drug-oligomer conjugate, a fatty acid component, and a bile salt component are described. The drug is covalently coupled to an oligomeric moiety. The fatty acid component and the bile salt component are present in a weight-to-weight ratio of between 1:5 and 5:1. Methods of treating diseases in a subject in need of such treatment using such pharmaceutical compositions are also provided, as are methods of providing such pharmaceutical compositions.

  描述了包括药物-寡聚物共轭物、脂肪酸成分和胆盐成分的药物组合物。药物以共价键连接到寡聚物基团上。脂肪酸成分和胆盐成分以1:5至5:1的重量比存在。还提供了利用这种药物组合物治疗需要此类治疗的受试者的方法，以及提供这种药物组合物的方法。
• Dibenzyl Amine Compounds and Derivatives
  申请人：Chang George

  公开号：US20070213371A1

  公开（公告）日：2007-09-13

  Dibenzyl amine compounds and derivatives, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.

  二苯基胺化合物及其衍生物，含有这种化合物的药物组合物以及使用这种化合物提高某些血浆脂质水平，包括高密度脂蛋白胆固醇，并降低其他一些血浆脂质水平，如低密度脂蛋白胆固醇和甘油三酯，并据此治疗由高密度脂蛋白胆固醇水平低和/或低密度脂蛋白胆固醇和甘油三酯水平高加重的疾病，如动脉粥样硬化和心血管疾病在某些哺乳动物，包括人类。
• [EN] NEW BIARYL AMIDE DERIVATIVES<br/>[FR] NOUVEAUX DÉRIVÉS DE BIARYLAMIDE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2012089601A1

  公开（公告）日：2012-07-05

  The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12 and A are as described herein, compositions including the compounds and methods of using the compounds.

  这项发明提供了具有通式（I）的新化合物，其中R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12和A如本文所述，包括这些化合物的组合物以及使用这些化合物的方法。
• Novel compounds useful for bradykinin B1 receptor antagonism
  申请人：Tung S. Jay

  公开号：US20060217362A1

  公开（公告）日：2006-09-28

  Disclosed are compounds that are bradykinin B 1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B 1 receptor. Certain of the compounds exhibit increased potency and are also expected to exhibit increased duration of action.

  揭示了一些化合物，它们是激肽酶B1受体拮抗剂，可用于治疗哺乳动物中由激肽酶B1受体介导的疾病，或缓解与疾病状况相关的不良症状。其中某些化合物表现出增强的效力，并且预计还将表现出延长的作用持续时间。
• Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
  申请人：——

  公开号：US20030228275A1

  公开（公告）日：2003-12-11

  A non-polydispersed mixture of conjugates in which each conjugate in the mixture comprises a drug coupled to an oligomer that includes a polyalkylene glycol moiety is disclosed. The mixture may exhibit higher in vivo activity than a polydispersed mixture of similar conjugates. The mixture may be more effective at surviving an in vitro model of intestinal digestion than polydispersed mixtures of similar conjugates. The mixture may result in less inter-subject variability than polydispersed mixtures of similar conjugates.

  披露了一种非多分散混合物，其中混合物中的每个共轭物包括与包含聚乙二醇基团的寡聚物偶联的药物。该混合物可能表现出比类似共轭物的多分散混合物更高的体内活性。该混合物可能比类似共轭物的多分散混合物更有效地在体外模拟肠道消化模型中存活。该混合物可能导致比类似共轭物的多分散混合物更少的受试者间变异性。